Urinary angiotensinogen as a potential biomarker of diabetic nephropathy

Clinical Kidney Journal

Volumn 7, Issue 4, 2014, Pages 354-360

  Satirapoj, Bancha ^a   Siritaweesuk, Nuttawut ^a   Supasyndh, Ouppatham ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

biomarker; diabetic nephropathy; renin angiotensin aldosterone system; urinary angiotensinogen

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BIOLOGICAL MARKER; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; URINALYSIS; URINARY EXCRETION;

EID: 84905176755     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu059     Document Type: Article

References (27)

1. Collins AJ, Foley RN, Chavers B et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012; 59(1 Suppl 1): A7, e1-420
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
3. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai 2010; 93(Suppl 6): S228-S241
4. Tabaei BP, Al-Kassab AS, Ilag LL et al. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24: 1560-1566
5. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45
6. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002; 61: 579-585
7. Kobori H, Prieto-Carrasquero MC, Ozawa Y et al. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 2004; 43: 1126-1132
8. Favaro S, Baggio B, Castellani A et al. Urinary angiotensinogen loss in chronic proteinuric glomerulonephritis. Int Urol Nephrol 1972; 4: 195-198
9. Saito T, Urushihara M, Kotani Y et al. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci 2009; 338: 478-480
10. Kamiyama M, Urushihara M, Morikawa T et al. Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int J Mol Sci 2013; 14: 23045-23062
11. Sawaguchi M, Araki SI, Kobori H et al. Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. J Diabetes Investig 2012; 3: 318-324
12. Kidney Disease: Improving Global Outcomes CKDWork Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease kidnedisease. Kidney Int Suppl 2013; 3: 136-150
13. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71: 169-180
14. Kobori H, Ozawa Y, Suzaki Y et al. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol 2005; 16: 2073-2080
15. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension 2001; 37: 1329-1335
16. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005; 288: F1183-F1190
17. Suzaki Y, Ozawa Y, Kobori H. Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 2007; 3: 40-46
18. Liu F, Brezniceanu ML, Wei CC et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008; 19: 269-280
19. Persson F, Lu X, Rossing P et al. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens 2013; 31: 1646-1652
20. Yamamoto T, Nakagawa T, Suzuki H et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J AmSoc Nephrol 2007; 18: 1558-1565
21. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637
22. Miyata K, Ohashi N, Suzaki Y et al. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol 2008; 35: 922-927
23. Kamiyama M, Zsombok A, Kobori H. Urinary angiotensinogen as a novel early biomarker of intrarenal renin-angiotensin system activation in experimental type 1 diabetes. J Pharmacol Sci 2012; 119: 314-323
24. Urushihara M, Kagami S. Urinary angiotensinogen as a biomarker of nephropathy in childhood. Int J Nephrol 2011; 2011: 206835
25. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
26. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961
27. Ogawa S, Kobori H, Ohashi N et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009; 4: 97-102